The AstraZeneca plant in Westborough has announced it will shut its doors permanently by the end of 2015. This is the final step the company has taken to shut down the plant, having already decreased employee levels there from 800 to just 180. More employees will be relieved by March, but others will remain employed until the company closes at the end of 2015.
The closing of the facility means the city of Westborough will lose its biggest taxpayer. The AstraZeneca plant pays the city an estimated $2 million in total; $360,000 in property taxes and $1,548,547 for equipment taxes. Residents and businesses in Westborough will begin to feel the pinch of the revenue loss in fiscal year 2017.
City officials hope to fill the vacancy quickly. The building is 420,000 square feet and could be a great site for a wide spectrum of businesses.
The AstraZeneca plant processed the asthma treatment Pulmicort Respules, which will now be produced at the company’s locations in Sweden and Australia. A company representative stated the move is to attain “increased efficiencies in our global supply chain.”
AstraZeneca will continue to house its research-and-development operations in Massachusetts, with facilities in both Waltham and Cambridge.